Ocular Therapeutix Growth, Revenue, Number of Employees and Funding
Revenue & Financials
- Ocular Therapeutix's revenue is currently $2M per year.
- Ocular Therapeutix received $37.5M in venture funding in February 2019.
- Ocular Therapeutix's revenue per employee is $11307
- Ocular Therapeutix's total funding is $187.9M.
- Ocular Therapeutix has 176 Employees.
- Ocular Therapeutix grew their employee count by 47% last year.
- Ocular Therapeutix currently has 35 job openings.
What Is Ocular Therapeutix?
Ocular Therapeutix, Inc. is a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative therapies for diseases and conditions of the eye using its proprietary hydrogel-based formulation technology. Ocular Therapeutix's lead product candidate, DEXTENZA (dexamethasone insert) 0.4 mg for intracanalicular use, has completed Phase 3 clinical development for the treatment of ocular pain and inflammation following ophthalmic surgery. OTX-TP (travoprost insert) is in Phase 3 clinical development for the reduction of intraocular pressure in patients with glaucoma and ocular hypertension. The Company's earlier stage assets include OTX-TIC, a sustained release travoprost intracameral injection for the reduction in intraocular pressure in patients with glaucoma and ocular hypertension, as well as sustained release intravitreal injections for the treatment of retinal diseases. These injections include the development of OTX-TKI, a tyrosine kinase inhibitor (TKI), and, in collaboration with Regeneron, an extended release protein-based anti-vascular endothelial growth factor (VEGF) trap. Ocular Therapeutix's first product, ReSure® Sealant, is FDA-approved to seal corneal incisions following cataract surgery.keywords:Biotechnology,Healthcare,Medical Devices,Pharmaceuticals
Number of Employees
Employee Growth %
|Name||Revenue||Number of Employees||Employee Growth||Total Funding|
|Long Term Pharm...||$9.4M||51||9%|
|Frenova Renal R...||$10.6M||60||15%|
Ocular Therapeutix News
Today, a Director at Ocular Therapeutix (OCUL – Research Report), Heier Jeffrey, bought shares of OCUL for $99.6K. This recent transaction
Ocular Therapeutix (NASDAQ:OCUL) Q4 2018 Earnings Conference Call March 7, 2019 4:30 PM ET. Company Participants. Antony Mattessich
The shares of Ocular Therapeutix jumped 15% in trading Friday as the company entered into a debt facility with favorable terms. This lifted an
Ocular Therapeutix Funding
|2017-01-25||$25.0M||Undisclosed||Cantor Fitzgerald & Co||Article|
|2018-01-26||$37.3M||Undisclosed||Piper Jaffray & Co||Article|
Ocular Therapeutix Executive Hires
|2016-01-12||Jonathan H. Talamo||Chief Medical Officer||Article|
|2016-10-21||Andy Hurley||Chief Commercial Officer||Article|
|2017-04-07||George Migausky||Interim Chief Financial Officer||Article|
|2017-08-04||Daniel Bollag||SVP Regulatory Affairs, Pharmacovigilance/Quality||Article|
|2017-09-26||Donald Notman||Chief Financial Officer||Article|
|2018-01-09||Kevin Hanley||SVP Technical Operations||Article|
|2018-12-07||Chad Brines||Vice President, Sales||Article|
Ocular Therapeutix Staff Cuts
|Date||Number of Employees||Location||Reference|